Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Decreased beta-amyloid peptide42 in cerebrospinal fluid of patients with progressive supranuclear palsy and corticobasal degeneration.

Journal of the neurological sciences - 15 Oct 2005

Noguchi Moeko, Yoshita Mitsuhiro, Matsumoto Yasuko, Ono Kenjiro, Iwasa Kazuo, Yamada Masahito

Abstract excerpt

Several previous studies have identified biochemical markers for Alzheimer's disease (AD): cerebrospinal fluid (CSF)-beta-amyloid peptide42 (CSF-Abeta42), CSF-total tau protein (CSF-tau) and CSF-phosphorylated tau protein (CSF-ptau). Progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) as well as AD are diseases with tauopathies. CSF-Abeta42, CSF-tau, and CSF-ptau have not been rigorously...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amyloid beta-Peptides
Share to Basal Ganglia Diseases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neurodegenerative Diseases

Share to Neuropsychological Tests

Share to Peptide Fragments

Share to ROC Curve

Share to Supranuclear Palsy, Progressive

Share to tau Proteins

Source

Identifiers

PMID: 15992827
DOI: 10.1016/j.jns.2005.05.015

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Decreased beta-amyloid peptide42 in cerebrospinal fluid of patients with progressive supranuclear palsy and corticobasal degeneration.PMID 15992827Read ↗

CSF-tau, CSF-Abeta1-42, ApoE-genotype and clinical parameters in the diagnosis of Alzheimer's disease: combination of CSF-tau and MMSE yields highest sensitivity and specificity.Semantic proximity Read ↗

Biochemical diagnosis of Alzheimer disease by measuring the cerebrospinal fluid ratio of phosphorylated tau protein to beta-amyloid peptide42.Semantic proximity Read ↗

Current application of neurochemical biomarkers in the prediction and differential diagnosis of Alzheimer's disease and other neurodegenerative dementias.Semantic proximity Read ↗

CSF Aβ42 and Aβ42/Aβ40 Ratio in Alzheimer’s Disease and Frontotemporal DementiasSemantic proximity Read ↗

Cerebrospinal fluid tau, p-tau 181 and amyloid-β38/40/42 in frontotemporal dementias and primary progressive aphasias.Semantic proximity Read ↗

Primary Tau Pathology, Not Copathology, Correlates With Clinical Symptoms in PSP and CBD.Semantic proximity Read ↗

Progressive supranuclear palsy: a systematic review.Semantic proximity Read ↗

Beta-amlyoid 1-42 and tau-protein in cerebrospinal fluid of patients with Parkinson's disease dementia.Semantic proximity Read ↗

Neurofibrillary Degeneration in Progressive Supranuclear Palsy and Corticobasal DegenerationSemantic proximity Read ↗

Amyloid beta protein 1-40 and 1-42 levels in matched cerebrospinal fluid and plasma from patients with Alzheimer disease.Semantic proximity Read ↗

Abnormal Amyloidogenesis Identified in Plasma of Patients with Spinocerebellar Ataxia Type 12.Semantic proximity Read ↗

Cerebrospinal Fluid Biomarker Profile in TDP-43-Related Genetic Frontotemporal DementiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.